Vascular News’ top 10 most popular stories of September 2022

4007

popularSeptember’s top 10 highlights a randomised trial that aims to examine early endovascular aneurysm repair (EVAR) in women, new radiation safety guidelines from the European Society for Vascular Surgery (ESVS), and the latest data from renal denervation trials, among various other updates from the vascular surgery world.

1. WARRIORS randomised trial aims to examine early EVAR in women

In September, a multinational collaboration of researchers received endorsement from the Global Cardiovascular Research Funders Forum (GCRFF) Multinational Clinical Trials Initiative for the WARRIORS (Women’s abdominal aortic aneurysm research: repair immediately or routine surveillance) trial.

2. Bentley acquires GoBack catheter from Upstream Peripheral Medical Technologies

Bentley recently announced that it has acquired the rights of the GoBack catheter from Upstream Peripheral Technologies. Martijn Nugteren, director Sales & Marketing, Bentley, says, “We will be really busy in the months ahead. Not only because we want to make the product commercially available in additional markets, but also due to the fact that we are going to rebrand the GoBack to BeBack. This is to make sure that our new product will be recognised as another leading product underneath Bentley’s brand umbrella.”

3. SAVAL trial finds no gains with custom drug-eluting stents in PAD below the knee

Day one of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain) put a strong focus on peripheral arterial disease (PAD). At a [email protected] session, Hans van Overhagen (Haga Teaching Hospital, Den Haag, The Netherlands), as European principal investigator, presented the primary results of the SAVAL trial.

4. ESVS publishes “pioneering” clinical practice guidelines on radiation safety

The European Society for Vascular Surgery (ESVS) has released clinical practice guidelines on radiation safety, which the writing committee notes are the first guidelines on the topic to be published under the auspices of a vascular surgical society. The guidelines were published online ahead of print in the European Journal of Vascular and Endovascular Surgery (EJVES) and presented for the first time at this year’s ESVS annual meeting (ESVS 2022; 20–23 September, Rome, Italy).

5. Medtronic receives CE mark for the first balloon-expandable covered stent indicated for ChEVAR

Medtronic announced that it has recently received CE mark for its Radiant balloon-expandable covered stent, the first and currently, only, covered stent indicated for use in chimney endovascular aneurysm repair (ChEVAR) with the Endurant II/IIs stent graft system.

6. Arteriovenous graft use linked to venous thromboembolism risk in haemodialysis patients

In an observational cohort study of Medicare beneficiaries receiving haemodialysis, the use of an arteriovenous graft (AVG) compared with an arteriovenous fistula (AVF) was associated with an increased risk of deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Conversely, researchers also found that there was little to no difference according to the access type in the rates of major bleeding or other cardiovascular outcomes. These results were recently published in Kidney Medicine.

7. Vascade vascular and venous closure devices gain CE mark

Haemonetics Corporation has received CE mark certification for its Vascade vascular closure and Vascade MVP venous vascular closure systems.

8. Silk Road Medical announces first patient enrolled in ROADSTER 3 post-approval study

Silk Road Medical has announced enrolment of the first patient in ROADSTER 3, which the company claims is the the first prospective, multicentre, single-arm study to assess real-world treatment of standard surgical risk patients with carotid artery disease using transcarotid artery revascularisation (TCAR). The procedure was performed by Animesh Rathore at Sentara Norfolk General Hospital in Norfolk, USA.

9. TCT 2022 hears “important data” from renal denervation trials

Findings from the RADIANCE II randomised pivotal trial, presented at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September, Boston, USA), “confirm that ultrasound renal denervation lowers blood pressure across the spectrum of hypertension”.

10. Penumbra and Asahi Intecc partner to introduce Indigo System to Japan

Penumbra and Asahi Intecc, a Japanese medical device manufacturer, announced that they will collaborate to introduce Penumbra’s Indigo Aspiration System into the Japanese market upon regulatory approval.


LEAVE A REPLY

Please enter your comment!
Please enter your name here